4.6 Review Book Chapter

Modulating NRF2 in Disease: Timing Is Everything

期刊

出版社

ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010818-021856

关键词

cancer; clinical trials; disease; KEAP1; NRF2; therapeutics

资金

  1. NIDDK NIH HHS [R01 DK109555] Funding Source: Medline
  2. NIEHS NIH HHS [R01 ES026845, R01 ES015010, R01 ES023758, P42 ES004940, P30 ES006694] Funding Source: Medline
  3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK109555] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES026845, R01ES023758, P42ES004940, P30ES006694] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The transcription factor nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) is a central regulator of redox, metabolic, and protein homeostasis that intersects with many other signaling cascades. Although the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. The discovery of new therapies is confounded by the fact that NRF2 levels vary significantly depending on physiological and pathological context. Thus, properly timed and targeted manipulation of the NRF2 pathway is critical in creating effective therapeutic regimens. In this review, we summarize the regulation and downstream targets of NRF2. Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据